Wells Fargo Upgrades Charles River Labs (CRL) to Outperform on Major Sell-Off
Tweet Send to a FriendGet Alerts CRL Hot Sheet
Price: $44.39 +0.09%
Rating Summary:
4 Buy, 7 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
4 Buy, 7 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade CRL Now!
Wells Fargo upgraded Charles River Labs (NYSE: CRL) from Market Perform to Outperform with a valuation range of $40-$42, saying shares are oversold following Wednesday's 9% swoon on guidance.
The firm comments, "We are upgrading shares of CRL to Outperform from Market Perform following the company's 2013 guidance announcement yesterday (12/12). We think shares are oversold after a 9% decline (vs. an increase of 0.04% in the S&P 500), given that the guidance midpoint is only 5% below consensus. We also think guidance is conservative based on (1) our modeling of FX, (2) accretion from Vital River, and (3) potential upside from partnerships. We believe this is a good entry point because we think 2013 could be the beginning of a slow improvement in the preclinical portion of the market."
The firm cut 2012E/2013E EPS to $2.69/$2.90 from $2.72/$2.99 previously.
For an analyst ratings summary and ratings history on Charles River Labs click here. For more ratings news on Charles River Labs click here.
Shares of Charles River Labs closed at $35.65 yesterday, with a 52 week range of $25.52-$41.64.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm comments, "We are upgrading shares of CRL to Outperform from Market Perform following the company's 2013 guidance announcement yesterday (12/12). We think shares are oversold after a 9% decline (vs. an increase of 0.04% in the S&P 500), given that the guidance midpoint is only 5% below consensus. We also think guidance is conservative based on (1) our modeling of FX, (2) accretion from Vital River, and (3) potential upside from partnerships. We believe this is a good entry point because we think 2013 could be the beginning of a slow improvement in the preclinical portion of the market."
The firm cut 2012E/2013E EPS to $2.69/$2.90 from $2.72/$2.99 previously.
For an analyst ratings summary and ratings history on Charles River Labs click here. For more ratings news on Charles River Labs click here.
Shares of Charles River Labs closed at $35.65 yesterday, with a 52 week range of $25.52-$41.64.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: A.G. Lafley Gives Procter & Gamble (PG) Investors 'New Hope', UBS Upgrades to Buy
- Deutsche Bank Upgrades Seagate (STX) to Buy; Sanmina (SANM) Cut to Sell, Flextronics (FLEX) & Fabrinet (FN) Cut to Hold
- Needham & Company Boosts Numbers on Infoblox (BLOX) on Strong Q3
Create E-mail Alert Related Categories
Analyst EPS Change, UpgradesRelated Entities
Standard & Poor's, Wells Fargo
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
